Skip to main content

Table 2 Chromosomal translocations and fusion proteins in hematologic malignancies involving ALK gene

From: Novel ALK inhibitors in clinical use and development

Disease

Chromosomal rearrangement

Fusion protein

Frequency (%)

Reference

ALCL

t(2;5)(p23;q35)

NPM-ALK

75-80

[9]

 

t(2;17)(p23;q25)

ALO17-ALK

<1

[34]

 

t(2;3)(p23;q21)

TFG-ALK

2

[48]

 

t(2;X)(p32;q11-q12)

MSN-ALK

<1

[44]

 

t(1;2)(q25;p23)

TPM3-ALK

12-18

[22]

 

t(2;19)(p23;p13)

TPM4-ALK

<1

[30]

 

inv(2)(p23;q35)

ATIC-ALK

2

[31]

 

t(2;22)(p23;q11.2)

MYH9-ALK

<1

[37]

 

t(2;17)(p23;q23)

CLTCL-ALK

2

[58]

DLBCL

t(2;5)(p23;q35)

NPM-ALK

ND

[10]

 

t(2;17)(p23;q23)

CLTC1-ALK

ND

[41]

 

t(2;5)(p23.1;q35.3)

SQSTM1-ALK

ND

[54]

 

ins(4)(2;4)(p23;q21)

SQSTM1-ALK

ND

[56]

 

t(2;4)(p24;q21)

SEC31A-ALK

ND

[45]

HL

t(2;5)(p23;q35)

NPM-ALK

ND

[1]

  1. ALCL; anaplastic large cell lymphoma, DLBCL; diffuse large B cell lymphoma; HL: Hodgkin lymphoma; ND; not determined.